Apnimed Q2 FY26 net income swings to USD 125.94 million; revenue falls 29.38% to USD 12.08 million

• Apnimed swung to net income of $125.94 million in Q2 2026 from a net loss a year earlier.
• Revenue fell 29.38% to $12.08 million, while R&D expenses dropped 38% to $9.9 million.
• General and administrative costs more than doubled to $12.67 million on higher legal services and launch-readiness spending.
• FDA accepted the NDA for AD109, proposed proprietary name Oxnimbi, setting a PDUFA target action date of Feb. 28, 2027.
• Cash and cash equivalents totaled $172.8 million at June 30; the company later completed a $220.8 million IPO at $16 a share.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Apnimed Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202609081639PRIMZONEFULLFEED9823206) on September 08, 2026, and is solely responsible for the information contained therein.